CrossrefInfokarte
Combination of Talquetamab and Pomalidomide in relapse-refractory high-risk Multiple Myeloma, including refractoriness to Mezigdomide
International Journal of Cancer Care and Delivery · 2025
DOI: 10.53876/001a.129573 ↗Abstract
Kein Abstract verfügbar.
EUVIMED